glp 1 agonist in ckd Glucagon-like peptide 1(GLP-1) receptor agonists the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist Real-World Evidence for GLP-1 Receptor

21 patients received subcutaneous exenatide injections, while 24 patients continued their conventional PD treatment

Pfizer's decision to halt development of the drug came after "a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators," according to a release

he consults for Eisai, Lilly, NeuroTherapia, Signant Health, Novo Nordisk, Anavex Life Sciences, Alzheon, Cognito Therapeutics, GSK and AbbVie

Therefore, localized delivery methods, such as intravitreal implants, nanoparticle carriers, or gene therapy aimed at retinal GLP-1R expression, are essential for maximizing therapeutic effectiveness while minimizing systemic exposure

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

Meta-analyses were performed on eligible studies that presented numerical data on the changes in select body composition and anthropometric parameters with GLP-1-based treatment